Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
OptimizeRxÂŽ (OPRX) provides unique physician and consumer platforms and strategie...
OptimizeRxÂŽ (OPRX) provides unique physician a...
Maternova, Inc. is the trusted resource for cutting edge medical innovations in ne...
Maternova, Inc. is the trusted resource for cut...
Prevail Therapeutics is applying precision medicine to the development of gene the...
Prevail Therapeutics is applying precision medi...
BiondVax is an innovative biopharmaceutical company developing a universal flu vac...
BiondVax is an innovative biopharmaceutical com...
Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on ...
Karyopharm Therapeutics is an innovation-driven...
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing thera...
At Catabasis Pharmaceuticals, our mission is to...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.